Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于股东无偿捐赠部分公司股份计划的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a shareholder's plan to donate a portion of company shares to an educational foundation. It details the shareholder's identity, the donation plan, the recipient's information, the donation agreement, and the shareholding changes before and after the donation. There is no financial data, earnings information, or report attached or referenced as being published. The document is a regulatory announcement about a share donation plan, which is a capital-related event but not a financing update or share issuance. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a specific announcement about a shareholder's donation of shares, which is best classified under Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory disclosure of a corporate event.
2026-04-29 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' issued by a certified public accounting firm for the company Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It specifically addresses the audit of the effectiveness of internal control over financial reporting as of December 31, 2025. The content includes the auditor's responsibilities, the company's responsibilities, and the auditor's opinion on the effectiveness of internal controls. There is no indication that this is a full annual report or interim financial report; rather, it is a standalone audit report focused on internal control. The document length is about 3113 characters, which is relatively short but contains the full audit opinion text, not just an announcement. Therefore, it fits the category of an Audit Report / Information (AR).
2026-04-29 Chinese
关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and nomination of the company's new board of directors, including detailed candidate biographies and compliance with relevant laws and regulations. It discusses the board re-election process, qualifications of candidates, and the upcoming shareholder meeting to approve the new board. There is no financial data, earnings information, or audit content. The document is clearly about changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The length and detail confirm it is not a brief announcement or a proxy solicitation but a formal disclosure of board changes.
2026-04-29 Chinese
独立董事候选人声明与承诺（刘浩）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate, Liu Hao, for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the candidate's qualifications, independence, compliance with relevant laws and regulations, and commitment to fulfill the duties of an independent director. There are no financial statements, audit information, voting results, or other report types present. The document is a formal statement related to board/management information, specifically about a board candidate's qualifications and commitments. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 2211 characters, which is short and focused on a specific management-related declaration, not a report or announcement of a report.
2026-04-29 Chinese
关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an upcoming investor performance explanation meeting (业绩说明会) scheduled for May 11, 2026. It mentions that the company will release its 2025 annual report and 2026 first quarter report on April 30, 2026, but this document itself is not the report. Instead, it is an announcement about the meeting where the company will discuss these reports and answer investor questions. The document is relatively short (1457 characters) and serves as a notice for the event rather than containing financial data or the report itself. Therefore, it fits the category of an Investor Presentation (IP) or possibly a Report Publication Announcement (RPA). However, since it is specifically about an investor meeting to explain performance and interact with investors, the best fit is Investor Presentation (IP).
2026-04-28 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by the information disclosure obligor (Finer Pharma Inc.) in Shanghai Xuantai Pharmaceutical Technology Co., Ltd. The document includes specifics about the shareholding before and after the change, the method of change (concentrated bidding and block trading), dates of transactions, and legal compliance statements. It is a formal report disclosing changes in significant share ownership levels, consistent with notifications required when crossing ownership thresholds. There is no indication that this is an annual report, earnings release, or any other type of financial or management report. The content matches the definition of a Major Shareholding Notification (MRQ). The document length is over 6000 characters and contains detailed data, so it is not a mere announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2026-04-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.